Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cumberland Pharmaceuticals Inc's Business Segments
Cumberland Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Product - Talicia
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product - Talicia0%
- Product - Sancuso0%
- Talicia0%
- Caldolor0%
- Other revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product - Talicia | $ 4 | - |
| Product - Sancuso | $ 4 | - |
| Talicia | $ 2 | - |
2 more segments available
Sign in to unlock the full Cumberland Pharmaceuticals Inc dataset.
Revenue by Product & Service Category - FY
- Product - Talicia0%
- Product - Sancuso0%
- Product - Vibativ0%
- Product - Caldolor0%
- Product - Kristalose0%
- Product - Other0%
- Product - Acetadote82.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product - Talicia | $ 2 | - |
| Product - Sancuso | $ 2 | - |
| Product - Vibativ | $ 2 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Cumberland Pharmaceuticals Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product - Talicia0%
- Product - Sancuso0%
- Talicia0%
- Caldolor0%
- Other revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product - Talicia | $ 4 | - |
| Product - Sancuso | $ 4 | - |
| Talicia | $ 2 | - |
2 more segments available
Sign in to unlock the full Cumberland Pharmaceuticals Inc dataset.
Description of Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that is headquartered in Nashville, Tennessee. The company specializes in the development, marketing, and distribution of branded prescription products for the treatment of acute care, gastroenterology, oncology, pain management, and ophthalmology.
Cumberland Pharmaceuticals was founded in 1999 by A.J. Kazimi, who currently serves as the Chief Executive Officer of the company. Since its inception, the company has developed and launched multiple products in the market, including its flagship product, Acetadote, which is primarily used as an antidote to acetaminophen toxicity.
The company's product portfolio includes Caldolor, a non-steroidal anti-inflammatory drug used for pain management, Kristalose, a prescription laxative used for the treatment of constipation, Hepatoren, a prescription product used for the management of hepatic encephalopathy, and Ethyol, a product used to reduce certain side effects associated with chemotherapy and radiation.
Cumberland Pharmaceuticals has a robust research and development program that involves both internal research efforts and collaborations with other pharmaceutical companies and academic institutions. The company has also established distribution partnerships with some of the leading pharmaceutical companies in the world, including Merck, Sanofi, and Lupin.
The company operates in the United States and several international markets, including Europe, the Middle East, and Asia. In addition to its pharmaceutical business, Cumberland also has a medical products division that develops and markets medical accessories and devices used in the healthcare industry.
According to its latest financial reports, Cumberland Pharmaceuticals recorded sales of $99 million in 2020, up from $98 million in the previous year, and had a workforce of approximately 180 employees. The company has received several awards and recognitions for its innovation and contribution to the pharmaceutical industry, including being named one of the fastest-growing companies in the United States by Inc. Magazine.
Cumberland Pharmaceuticals was founded in 1999 by A.J. Kazimi, who currently serves as the Chief Executive Officer of the company. Since its inception, the company has developed and launched multiple products in the market, including its flagship product, Acetadote, which is primarily used as an antidote to acetaminophen toxicity.
The company's product portfolio includes Caldolor, a non-steroidal anti-inflammatory drug used for pain management, Kristalose, a prescription laxative used for the treatment of constipation, Hepatoren, a prescription product used for the management of hepatic encephalopathy, and Ethyol, a product used to reduce certain side effects associated with chemotherapy and radiation.
Cumberland Pharmaceuticals has a robust research and development program that involves both internal research efforts and collaborations with other pharmaceutical companies and academic institutions. The company has also established distribution partnerships with some of the leading pharmaceutical companies in the world, including Merck, Sanofi, and Lupin.
The company operates in the United States and several international markets, including Europe, the Middle East, and Asia. In addition to its pharmaceutical business, Cumberland also has a medical products division that develops and markets medical accessories and devices used in the healthcare industry.
According to its latest financial reports, Cumberland Pharmaceuticals recorded sales of $99 million in 2020, up from $98 million in the previous year, and had a workforce of approximately 180 employees. The company has received several awards and recognitions for its innovation and contribution to the pharmaceutical industry, including being named one of the fastest-growing companies in the United States by Inc. Magazine.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that primarily develops, markets, and distributes prescription pharmaceuticals. The company is strategically focused on several therapeutic segments, allowing it to create a comprehensive portfolio of innovative products. Below is an extensive look at the operational segments, product offerings, and supporting services of Cumberland Pharmaceuticals Inc.
Segments
Cumberland Pharmaceuticals operates through three principal segments:
1. Hospital Acute Care Segment
This segment is dedicated to products intended for use within hospital settings, particularly in high-stakes environments such as emergency departments, intensive care units (ICUs), and operating rooms. The emphasis here is on addressing urgent medical needs effectively and safely. Key products in this segment include:
- Acetadote: An intravenous medication specifically formulated to treat acetaminophen overdose, helping to mitigate potentially severe liver damage.
- Caldolor: A non-steroidal anti-inflammatory drug (NSAID) available in an injectable form for the management of moderate to severe pain and fever. It provides an option that can be utilized in environments where oral administration is not feasible.
- Vaprisol: Used primarily for treating hyponatremia, or low sodium levels in the blood, Vaprisol addresses critical electrolyte imbalances, often encountered in acute care settings.
Inflammatory Segment
Focusing on treatment options for inflammatory conditions, this segment includes a variety of products designed to alleviate symptoms related to inflammation and its complications. Notable products include:
- Kristalose: A prescription laxative that facilitates bowel movements, used primarily to treat constipation due to its osmotic properties.
- Omeclamox-Pak: A combination antibiotic therapy aimed at eradicating Helicobacter pylori infections, which are common contributors to peptic ulcers and other gastrointestinal disorders.
- RediTrex: A pre-filled syringe of methotrexate used in low doses for the treatment of rheumatoid arthritis and other autoimmune diseases, as well as in higher doses for certain cancers.
Ethical Pharmaceuticals Segment
This segment covers products designed for various medical conditions, tailored to ethical guidelines and responsible use in clinical settings. The portfolio includes:
- Hepatoren: A pharmaceutical intended for the management of liver disease, supporting liver function and aiding in the therapeutic management of hepatic conditions.
- Boxaban: A medication aimed at preventing venous thromboembolic events such as blood clots, providing essential anticoagulant therapy in vulnerable patient populations.
- Vasculan: Used to treat peripheral arterial disease, this medication helps to improve blood flow and alleviate symptoms associated with vascular insufficiency.
Products
Cumberland Pharmaceuticals provides a diverse range of products that cater to various medical needs. The company’s offerings include both standalone medications and combination therapies, enhancing their therapeutic reach. Each product is developed with a focus on patient safety and efficacy, underlining the company’s commitment to providing high-quality healthcare solutions.
Services
In addition to its pharmaceutical products, Cumberland Pharmaceuticals also offers a suite of services designed to support healthcare providers, regulatory compliance, and product delivery. These services encompass:
1. Medical Affairs and Interactions
The company emphasizes robust medical affairs support, which includes providing education, scientific research backing, and ongoing educational opportunities for healthcare providers regarding their products.
Sales and Marketing
Cumberland has established a dedicated sales and marketing infrastructure to effectively promote its product lines. This team focuses on outreach to healthcare providers to ensure that key information about their products reaches decision-makers in the hospital and clinical settings.
Regulatory Affairs
Navigating the complex landscape of pharmaceutical regulations is critical, and Cumberland Pharmaceuticals provides expertise in drug development, facilitating successful product registration, labeling, and ongoing compliance with regulatory requirements.
Clinical Trials Management
The company offers comprehensive clinical trial management services, streamlining the process of executing clinical trials from planning through to execution, data collection, and analysis. This service is vital for advancing research proposals and demonstrating the safety and efficacy of new products.
Conclusion
Cumberland Pharmaceuticals Inc. maintains a versatile portfolio, engineered to meet the diverse needs of the healthcare sector. With a strong emphasis on the development and marketing of specialty prescription pharmaceuticals, the company prides itself on providing essential services that enhance patient outcomes and support healthcare providers. This multifaceted approach enables Cumberland Pharmaceuticals to effectively address critical medical issues across various therapeutic areas, solidifying its presence as a notable player in the specialty pharmaceuticals market.
Segments
Cumberland Pharmaceuticals operates through three principal segments:
1. Hospital Acute Care Segment
This segment is dedicated to products intended for use within hospital settings, particularly in high-stakes environments such as emergency departments, intensive care units (ICUs), and operating rooms. The emphasis here is on addressing urgent medical needs effectively and safely. Key products in this segment include:
- Acetadote: An intravenous medication specifically formulated to treat acetaminophen overdose, helping to mitigate potentially severe liver damage.
- Caldolor: A non-steroidal anti-inflammatory drug (NSAID) available in an injectable form for the management of moderate to severe pain and fever. It provides an option that can be utilized in environments where oral administration is not feasible.
- Vaprisol: Used primarily for treating hyponatremia, or low sodium levels in the blood, Vaprisol addresses critical electrolyte imbalances, often encountered in acute care settings.
Inflammatory Segment
Focusing on treatment options for inflammatory conditions, this segment includes a variety of products designed to alleviate symptoms related to inflammation and its complications. Notable products include:
- Kristalose: A prescription laxative that facilitates bowel movements, used primarily to treat constipation due to its osmotic properties.
- Omeclamox-Pak: A combination antibiotic therapy aimed at eradicating Helicobacter pylori infections, which are common contributors to peptic ulcers and other gastrointestinal disorders.
- RediTrex: A pre-filled syringe of methotrexate used in low doses for the treatment of rheumatoid arthritis and other autoimmune diseases, as well as in higher doses for certain cancers.
Ethical Pharmaceuticals Segment
This segment covers products designed for various medical conditions, tailored to ethical guidelines and responsible use in clinical settings. The portfolio includes:
- Hepatoren: A pharmaceutical intended for the management of liver disease, supporting liver function and aiding in the therapeutic management of hepatic conditions.
- Boxaban: A medication aimed at preventing venous thromboembolic events such as blood clots, providing essential anticoagulant therapy in vulnerable patient populations.
- Vasculan: Used to treat peripheral arterial disease, this medication helps to improve blood flow and alleviate symptoms associated with vascular insufficiency.
Products
Cumberland Pharmaceuticals provides a diverse range of products that cater to various medical needs. The company’s offerings include both standalone medications and combination therapies, enhancing their therapeutic reach. Each product is developed with a focus on patient safety and efficacy, underlining the company’s commitment to providing high-quality healthcare solutions.
Services
In addition to its pharmaceutical products, Cumberland Pharmaceuticals also offers a suite of services designed to support healthcare providers, regulatory compliance, and product delivery. These services encompass:
1. Medical Affairs and Interactions
The company emphasizes robust medical affairs support, which includes providing education, scientific research backing, and ongoing educational opportunities for healthcare providers regarding their products.
Sales and Marketing
Cumberland has established a dedicated sales and marketing infrastructure to effectively promote its product lines. This team focuses on outreach to healthcare providers to ensure that key information about their products reaches decision-makers in the hospital and clinical settings.
Regulatory Affairs
Navigating the complex landscape of pharmaceutical regulations is critical, and Cumberland Pharmaceuticals provides expertise in drug development, facilitating successful product registration, labeling, and ongoing compliance with regulatory requirements.
Clinical Trials Management
The company offers comprehensive clinical trial management services, streamlining the process of executing clinical trials from planning through to execution, data collection, and analysis. This service is vital for advancing research proposals and demonstrating the safety and efficacy of new products.
Conclusion
Cumberland Pharmaceuticals Inc. maintains a versatile portfolio, engineered to meet the diverse needs of the healthcare sector. With a strong emphasis on the development and marketing of specialty prescription pharmaceuticals, the company prides itself on providing essential services that enhance patient outcomes and support healthcare providers. This multifaceted approach enables Cumberland Pharmaceuticals to effectively address critical medical issues across various therapeutic areas, solidifying its presence as a notable player in the specialty pharmaceuticals market.